EQT Life Sciences Leads $75M Series B for Atalanta Therapeutics
- Editor
- Jan 28
- 2 min read
What's Happening: EQT Life Sciences is leading a $75 million Series B funding round for Atalanta Therapeutics, a Boston-based biotech company developing RNA interference (RNAi) treatments for neurological diseases. The funding will support Phase 1 clinical trials for Atalanta's therapies targeting KCNT1-related epilepsy and Huntington's disease.
The Key Moves:
Atalanta has developed a proprietary RNAi platform called di-siRNA, enabling RNAi deployment throughout the brain and spinal cord.
The Series B financing was co-led by Sanofi Ventures, with participation from new and existing investors.
Atalanta plans to submit IND applications next year to start Phase 1 trials for its KCNT1-related epilepsy and Huntington's disease programs.
By The Numbers :
The $75 million Series B brings Atalanta's total capital raised to $240 million, including previous financings and partnerships.
Atalanta aims to advance two investigational RNAi therapies to Phase 1 clinical trials.
The funding round included participation from RiverVest Venture Partners, abrdn, Inc., Mirae Asset Financial Group, and F-Prime Capital.
Key Quotes:
Alicia Secor, Atalanta's CEO: 'This Series B will support a path to the clinic for two programs for serious neurological diseases that today lack disease-modifying therapies.'
Arno de Wilde, EQT Life Sciences: 'Atalanta's di-siRNA technology has shown promising ability to durably and evenly silence disease-promoting genes throughout previously inaccessible regions of the brain and spinal cord.'
Arno de Wilde: 'EQT is proud to lead this investment in Atalanta's future as part of such a high-quality investor syndicate.'
The Bottom Line: EQT Life Sciences' investment in Atalanta Therapeutics represents a significant boost for the development of RNAi therapies targeting neurological diseases. The $75 million funding will accelerate Atalanta's progress towards clinical trials, potentially bringing new treatment options to patients with KCNT1-related epilepsy and Huntington's disease.
Comments